Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leavesup to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.

Biotechnology

Therapeutics

Synartro

Synartro's headquarters in Uppsala, Sweden

Description

People (2)

Fredrik Lehmann

Magnus Hurst

Jobs